With 11% of clinical research sites failing to enroll a single patient, and 37% of sites under-enrolling, the need for improved efficiency is evident. Studies involving fewer sites have potential to improve on this performance, taking advantage of the best leaders in each therapeutic area, reducing travel and administrative costs, and aligning processes for easier start-up.
This insight brief examines IQVIA’s innovative approaches to patient and site engagement, such as pioneering early planning, innovative partnerships, new technology and communication tools, working with patient advocacy groups, precision enrollment and the IQVIA Infosario Site Gateway platform.
Some 11% of research sites industry-wide fail to enroll a single patient, with 37% of sites under-enrolling, creating inefficiency and lost productivity.1 This represents a waste of time and money benefiting neither sponsors nor other research stakeholders. Studies involving fewer sites have potential to improve on this performance, taking advantage of the best leaders in each therapeutic area, reducing travel and administrative costs, and aligning processes for easier start-up.
Studies involving fewer sites hold promise in improving clinical trial efficiency, drawing on the expertise of therapeutic experts, minimizing costs and optimizing processes for easier start-up.
Early planning is a major factor in trial success – including identifying patient pathways in each country, understanding patient and investigator perspectives, and applying these insights to trial design and implementation. Patient advocacy groups are an important source of information about patient preferences, helping inform study design and tailored communication programs and flag potential enrollment and retention risks. For rare conditions, online sources of patient-generated content can also be mined using social listening tools to help understand how patients experience a particular condition. Early engagement with sites, clinical and medical teams, and in-country regulatory specialists is also critical to successful enrollment planning.
This insight brief examines new and innovative solutions to get drugs to patients faster, via improved patient and site engagement.